AKT1 and cancer: Importantly, our enrichment analysis uncovers the involvement of crucial cancer-related pathways, including 'PI3K-AKT signaling,' 'JAK-STAT signaling,' and 'ErbB signaling.' This holistic understanding highlights the significance of CuD's multitarget, multipathway approach in CRC treatment.